<DOC>
	<DOCNO>NCT00544804</DOCNO>
	<brief_summary>RATIONALE : Lapatinib may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase I trial study side effect best dose lapatinib treat patient advance metastatic breast cancer overexpresses HER2 .</brief_summary>
	<brief_title>Lapatinib Treating Patients With Advanced Metastatic Breast Cancer That Overexpresses HER2</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose ( MTD ) high-dose lapatinib ditosylate patient HER2-overexpressing advance metastatic breast cancer . - To determine dose-limiting toxicity drug patient . Secondary - To determine whether tumor HER2 completely inactivate lapatinib ditosylate MTD 5-day schedule . - To determine whether total inactivation HER2 decrease cardiac ejection fraction . OUTLINE : Patients stratify accord dose level . Patients receive escalate dos oral lapatinib ditosylate twice daily day 1-5 maximum tolerate dose determine . Courses repeat every 2 week absence disease progression unacceptable toxicity . Some patient undergo tumor tissue blood sample collection periodically biological correlative study . Samples analyze evidence cardiac injury , tumor target lysis effect , determine lapatinib serum level result inactivation tumor HER2 HER3 kinase oncogenic signaling . After completion study treatment , patient follow every 2 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer Advanced metastatic disease No effective curative therapy available Boneonly disease allow Tumor HER2 overexpression HER2 3+ expression immunohistochemistry OR &gt; 2fold ( HER2 2+ ) gene amplification fluorescence situ hybridization Evaluable disease Measurable disease require No progressive brain metastasis Hormone receptor status specify PATIENT CHARACTERISTICS : Inclusion criterion : ECOG performance status 02 Life expectancy &gt; 3 month Female Menopausal status specify Absolute neutrophil count ≥ 1,000 cells/mm^3 Hemoglobin ≥ 9 g/dL Platelet count ≥ 75,000 cells/mm^3 Total bilirubin normal AST ALT ≤ 3 x upper limit normal ( ULN ) ( ≤ 5 x ULN liver metastasis ) Creatinine normal OR creatinine clearance ≥ 40 mL/min INR ≤ 1.5 Potassium normal Magnesium normal Not pregnant Negative pregnancy test Fertile patient must use effective contraception prior study therapy Cardiac ejection fraction ≥ 50 % Consents 2 tumor fine needle aspiration biopsy biomarker analysis Lungonly disease site otherwise deem highrisk biopsy , requirement biopsy waive Exclusion criterion : History significant cardiac disease include follow : Congestive heart failure Symptomatic cardiac arrhythmia Unstable angina Uncontrolled prior lapatinib ditosylate therapy toxicity ≥ grade 2 Allergic reaction IV contrast dye despite standard prophylaxis History malabsorption syndrome disease significantly affect gastrointestinal function major resection stomach small bowel could affect absorption , distribution , metabolism , excretion study drug Conditions would impair patient 's ability swallow retain oral medication Concurrent disease condition would make patient inappropriate study participation would interfere patient 's safety Psychological , familial , sociological , geographical condition permit compliance protocol PRIOR CONCURRENT THERAPY : Prior lapatinib ditosylate trastuzumab allow At least 4 week since prior concurrent chemotherapy investigational anticancer agent At least 2 week since prior concurrent hormonal therapy At least 2 week since prior concurrent lapatinib ditosylate prohibit medication , include CYP3A4 inhibitor inducer , herbal supplement , gastric pH modifier More 4 week since prior radiotherapy No aspirin plavix therapy within 7 day prior tumor biopsy No concurrent coumadin Low molecular weight heparin allow provided hold least 24 hour prior tumor biopsy Concurrent gonadal suppression agent ( i.e. , Zoladex Lupron ) palliative bisphosphonates ( i.e. , Zometa ) allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>bone metastasis</keyword>
</DOC>